Embryonic stem cell trials for macular degeneration: a preliminary report.

By S. Schwartz, J. Hubschman, Gad Heilwell, V. Franco-Cárdenas, C. Pan, Rosaleen M Ostrick, Edmund Mickunas, R. Gay, I. Klimanskaya, R. Lanza. The Lancet, 2012

1,405 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5487b83d59f9421446fb3486336c8a332ef50241

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Dou
2. Mingjing Yan
3. A. Trounson
4. Jian Li
5. Jun Guo
6. Xiuqing Huang
7. Courtney A. McDonald
8. Weiqing Tang

Citations in the corpus

• Stem Cell Therapies in Clinical Trials: Progress and Challenges. (2015, background): “Preliminary results have been reported by the company Ocata Therapeutics (formally ACT) on clinical safety trials for the use of retinal pigmented epithelial cells (RPEs) derived from hESCs for dry macular degeneration and Stargardt’s macular dystrophy (Schwartz et al., 2012, 2015).”
• Aging and aging-related diseases: from molecular mechanisms to interventions and treatments (2022, background): “Transplantation of RPE cell monolayers or biological patches consisting of RPE monolayers derived from human embryonic stem cells into elderly patients with dry AMD results in improved corrected visual acuity.(644,645) In addition, treating AMD by transplanting RPE cells derived from skin fibroblast”